Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2020-02-25 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK
Foreign Filer Report
2020-02-25 English
AstraZeneca divests global rights to Movantik
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content details a specific corporate action: AstraZeneca divesting global rights to a drug (Movantik) to RedHill Biopharma, including financial considerations and strategic rationale. This type of announcement, which is a material corporate event disclosure but does not fit neatly into specific financial report categories (like 10-K, ER, or IR), is best classified as a general Regulatory Filing. Since the document explicitly mentions 'RNS Number' and is a standard market disclosure, the most appropriate code is RNS, which serves as the general regulatory announcement fallback.
2020-02-25 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2020-02-19 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is a 'TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES' under Article 19 of the EU Market Abuse Regulation. It details the purchase of shares by a Non-Executive Director (Michel Demaré). This type of insider transaction disclosure is specifically covered by the 'Director's Dealing' definition. Although it is distributed via RNS, the specific content points directly to DIRS, which takes precedence over the general RNS fallback.
2020-02-19 English
AZN: FULL-YEAR AND Q4 2019 RESULTS
Foreign Filer Report
2020-02-14 English
AZN: Full-year and Q4 2019 results
Earnings Release Classification · 100% confidence The document explicitly states it contains 'Full-year and Q4 2019 results' and provides detailed financial tables covering Product Sales, Revenue, Operating Profit, and EPS for the full year and the fourth quarter. It includes commentary from the CEO on performance and future guidance. This structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it covers the 'Full-year' results, it is more comprehensive than a typical quarterly earnings release, but it is not the full statutory 10-K. However, the content is a summary announcement of the results, not the full statutory filing. The presence of the RNS Number (9829C) and the date (14 February 2020) indicates this is a regulatory announcement of the results. Given the comprehensive nature of the financial data presented (full-year summary), it aligns best with an Earnings Release (ER) which typically precedes the full 10-K filing, or an Interim Report if it were only for a quarter. Since it covers the full year and is presented as an announcement via RNS, 'ER' is the most appropriate classification for this results summary. FY 2019
2020-02-14 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.